Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany.
Real-World and Advanced Analytics, Ingress-Health HWM GmbH - A Cytel Company, Berlin, Germany.
J Dermatolog Treat. 2024 Dec;35(1):2308682. doi: 10.1080/09546634.2024.2308682. Epub 2024 Jan 31.
The advent of biologics and janus kinase inhibitors has revolutionized treatment of atopic dermatitis (AD).
To investigate preferences of patients with AD for attributes of currently approved systemic treatments and assess influencing factors.
An online discrete choice experiment was conducted in patients with AD throughout Germany to analyze preferences for outcome (probability of (almost) clear skin at week 16, probability of significant itch improvement, time to onset of itch relief and type of side effects) and process attributes (application method and frequency of laboratory tests).
Participants ( = 182, 75.3% female) considered side effects (Relative Importance Score (RIS): 31.2), (almost) clear skin (RIS: 24.2) and probability of itch improvement (RIS: 16.0) most important. Application method (RIS: 14.4), time to onset of itch relief (RIS: 7.4) and frequency of laboratory tests (RIS: 6.8) were less relevant. Preferences were significantly influenced by sex, age, psychiatric comorbidity, current therapy and health-related quality of life according to multivariate regression analysis.
Participants attached great importance to safety and symptom control. However, preferences were also dependent on individual characteristics, underscoring the importance of personal counseling. Conjoined with medical considerations, patients' preferences have fundamental impact on shared decisions for treatment of AD.
生物制剂和 Janus 激酶抑制剂的出现彻底改变了特应性皮炎(AD)的治疗方法。
调查 AD 患者对目前批准的系统治疗属性的偏好,并评估影响因素。
在德国各地的 AD 患者中进行了一项在线离散选择实验,以分析对结果(第 16 周几乎无皮疹的概率、显著瘙痒改善的概率、瘙痒缓解开始时间和不良反应类型)和过程属性(应用方法和实验室检测频率)的偏好。
参与者( = 182,75.3%为女性)认为不良反应(相对重要性评分(RIS):31.2)、(几乎)无皮疹(RIS:24.2)和瘙痒改善概率(RIS:16.0)最重要。应用方法(RIS:14.4)、瘙痒缓解开始时间(RIS:7.4)和实验室检测频率(RIS:6.8)的相关性较低。多变量回归分析表明,偏好受性别、年龄、精神共病、当前治疗和健康相关生活质量的显著影响。
参与者非常重视安全性和症状控制。然而,偏好也取决于个体特征,这强调了个性化咨询的重要性。结合医学考虑因素,患者的偏好对 AD 治疗的共同决策具有根本影响。